Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Variant-Specific IgA Protects Against Omicron Infection.
Goh YS, Fong SW, Hor PX, Loh CY, Wang B, Salleh SNM, Ngoh EZX, Lee RTC, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lim C, Teo J, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES, Maurer-Stroh S, Wang CI, Leo YS, Lye DC, Young BE, Ng LFP, Renia L; NCID Study Group; COVID-19 Cohort Study Group. Goh YS, et al. Among authors: rao s. J Infect Dis. 2024 Aug 16;230(2):e287-e291. doi: 10.1093/infdis/jiad525. J Infect Dis. 2024. PMID: 37996071 Free PMC article. Clinical Trial.
Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.
Poh XY, Tan CW, Lee IR, Chavatte JM, Fong SW, Prince T, Hartley C, Yeoh AYY, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Lim C, Teo J, Lim DRX, Chia W, Hiscox JA, Ng LFP, Ren EC, Lin RTP, Renia L, Lye DC, Wang LF, Young BE. Poh XY, et al. Among authors: rao s. Clin Infect Dis. 2022 Dec 19;75(12):2088-2096. doi: 10.1093/cid/ciac345. Clin Infect Dis. 2022. PMID: 35543372 Free PMC article. Clinical Trial.
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
Poh XY, Lee IR, Lim C, Teo J, Rao S, Chia PY, Ong SWX, Lee TH, Lin RJH, Ng LFP, Ren EC, Lin RTP, Wang LF, Renia L, Lye DC, Young BE. Poh XY, et al. Among authors: rao s. Trials. 2022 Jun 16;23(1):498. doi: 10.1186/s13063-022-06345-2. Trials. 2022. PMID: 35710572 Free PMC article.
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters.
Rouers A, Wong N, Goh YS, Torres-Ruesta A, Tay MZ, Chang ZW, Fong SW, Neo V, Kam IKJ, Yeo NK, Huang Y, Loh CY, Hor PX, Wong JXE, Tan YJ; COVID-19 Study Group; Macary PA, Qian X, Bei W, Ngoh EZX, Salleh SNM, Wang CI, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lin RJH, Lim C, Teo J, Ren EC, Lye DC, Young BE, Ng LFP, Renia L. Rouers A, et al. Among authors: rao s. J Med Virol. 2023 Jan;95(1):e28258. doi: 10.1002/jmv.28258. Epub 2022 Nov 16. J Med Virol. 2023. PMID: 36305052 Free PMC article.
Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant.
Tay MZ, Goh YS, Fong SW, Chang ZW, Rouers A, Wong N, Torres-Ruesta A, Huang Y, Selvam SK, Hor PX, Loh CY, Wang B, Mohd Salleh SN, Ngoh EZX, Lee RTC, Neo V, Kam IKJ, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lim C, Teo J; NCID Study Group; PRIBIVAC Cohort Study Group; Maurer-Stroh S, Wang CI, Leo YS, Lin RTP, Lye DC, Young BE, Ng LFP, Renia L. Tay MZ, et al. Among authors: rao s. Lancet Reg Health West Pac. 2023 Apr;33:100732. doi: 10.1016/j.lanwpc.2023.100732. Epub 2023 Mar 7. Lancet Reg Health West Pac. 2023. PMID: 37125085 Free PMC article. No abstract available.
Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1).
Goh YS, Fong SW, Hor PX, Loh CY, Tay MZ, Wang B, Salleh SNM, Ngoh EZX, Lee RTC, Poh XY, Lee IR, Rao S, Chia PY; PRIBIVAC Cohort Study Group; Maurer-Stroh S, Wang CI, Leo YS, Lye DC, Young BE, Ng LFP, Renia L. Goh YS, et al. Among authors: rao s. Int J Infect Dis. 2024 Sep;146:107147. doi: 10.1016/j.ijid.2024.107147. Epub 2024 Jun 28. Int J Infect Dis. 2024. PMID: 38945433 Free article.
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.
Poh XY, Lee IR, Tan CW, Chavatte JM, Fong SW, Goh YS, Rouers A, Wong N, Torres-Ruesta A, Mah SYY, Yeoh AYY, Gandhi M, Rahman N, Chin YQ, Lim JJ, Yoong TJK, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Lim DRX, Chia W, Renia L, Ren EC, Lin RTP, Lye DC, Wang LF, Ng LFP, Young BE. Poh XY, et al. Among authors: rao s. EBioMedicine. 2024 Sep;107:105275. doi: 10.1016/j.ebiom.2024.105275. Epub 2024 Aug 12. EBioMedicine. 2024. PMID: 39137572 Free PMC article. Clinical Trial.
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
Poh XY, Torres-Ruesta A, Yoong T, Wong N, Tan CW, Rouers A, Chavatte JM, Goh YS, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Neo V, Kam IKJ, Huang Y, Hor PX, Loh CY; PRIBIVAC study group; Yeoh AY, Lim DRX, Chia W, Ren EC, Lin RTP, Fong SW, Renia L, Lye DC, Wang LF, Ng LFP, Young BE. Poh XY, et al. Among authors: rao s. Vaccine. 2024 Nov 14;42(25):126275. doi: 10.1016/j.vaccine.2024.126275. Epub 2024 Sep 5. Vaccine. 2024. PMID: 39241318 Free article. Clinical Trial.
9,809 results